References
- Mathers CD, Boerma T, Fat DM. Global and regional causes of death. Br Med Bull 2009;92:7–32.
- Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2014;383:245–54.
- Brown DL, Boden-Albala B, Langa KM, et al. Projected costs of ischemic stroke in the United States. Neurology 2006;67:1390–5.
- Kang HY, Lim SJ, Suh HS, Liew D. Estimating the lifetime economic burden of stroke according to the age of onset in South Korea: a cost of illness study. BMC Public Health 2011;11:646.
- O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376(9735):112–23.
- Canouï-Poitrine F, Luc G, Bard JM, et al. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study. Cerebrovasc Dis 2010;30(3):252–9.
- Holme I, Aastveit AH, Hammar N, et al. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009;265:275–87.
- Koren-Morag N, Goldbourt U, Graff E, Tanne D. Apolipoproteins B and A1 and the risk of ischemic cerebrovascular events in patients with preexisting atherothrombotic disease. J Neurol Sci 2008;270:82–7.
- Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr Opin Lipidol 2007;18:633–7.
- Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255:188–205.
- Schoenborn CA, Adams PE. Health behaviors of adults: United States, 2005–2007. Vital Health Stat 2010;10(245):80–1; Appendix II.
- Marcovina SM, Albers JJ, Kennedy H, et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994;40(4):586–92.
- Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke 2003;34:1364–9.
- Kim DE, Noh SM, Jeong SW, Cha MH. NINJ2 SNP may affect the onset age of first-ever ischemic stroke without increasing silent cerebrovascular lesions. BMC Res Notes 2012;5:155.
- Sniderman AD, Furberg CD. Age as a modifiable risk factor for cardiovascular disease. Lancet 2008;371:1547–9.
- Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Circulation 1996;94(3):273–8.
- Sabino AP, Sousa MDO, Lima LM, et al. ApoB/ApoA-I ratio in young patients with ischemic cerebral stroke or peripheral arterial disease. Trans Res 2008;152:113–8.
- Park JH, Hong KS, Lee EJ, et al. High levels of apolipoprotein B/AI ratio are associated with intracranial atherosclerotic stenosis. Stroke 2011;42:3040–6.
- Kostapanos MS, Christogiannis LG, Bika E, et al. Apolipoprotein B-to-A1 ratio as a predictor of acute ischemic nonembolic stroke in elderly subjects. J Stroke Cerebrovasc Dis 2010;19(6):497–502.